Alcolase ApS has developed a proprietary enzyme system that breaks down alcohol in the stomach before it enters the bloodstream, enabling individuals with alcohol intolerance to enjoy their favorite beverages without adverse effects. This technology addresses the challenges faced by alcohol-intolerant individuals, promoting a healthier drinking experience.
Funding
€1.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BADVMIFounders
Product
Problem
Many individuals experience alcohol intolerance, leading to unpleasant symptoms after consuming alcoholic beverages. This intolerance can limit social experiences and prevent individuals from enjoying alcoholic drinks without adverse effects.
Solution
Alcolase ApS has developed a proprietary enzyme system designed to break down alcohol in the stomach before it enters the bloodstream. This innovative approach aims to mitigate the effects of alcohol intolerance, allowing individuals to consume alcoholic beverages with reduced discomfort. The enzyme system works by accelerating the metabolism of alcohol in the stomach, thereby reducing the amount of alcohol that is absorbed into the bloodstream. This can lead to a more enjoyable and symptom-free experience for those with alcohol intolerance.
Target Audience
The primary target audience includes individuals who experience symptoms of alcohol intolerance, such as flushing, headaches, or nausea, after consuming alcoholic beverages.
Features
- Proprietary enzyme formulation specifically designed for alcohol breakdown.
- Targets alcohol metabolism in the stomach to reduce bloodstream absorption.
- Easy to administer, likely in pill or powder form (inferred).